CGON CG Oncology, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1991792 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY183.6%
TTM net income YoY-56.8%
TTM EPS YoY-34.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-4,293.5%
Net margin-3,851.1%
FCF margin-3,068.0%
EBITDA margin-4,237.7%
Returns
ROE-28.3%
ROA-26.7%
ROIC (approx.)-26.0%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets5.3%
Debt / equity0.00x
Current ratio21.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-5.6%
Payout ratio—
Capex / revenue30.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $4.04M | $1.14M | $204,000 |
| R&D expense | $116.64M | $82.10M | $45.75M |
| SG&A expense | $73.53M | $33.70M | $9.90M |
| Operating income | -$190.77M | -$114.67M | -$55.45M |
| Income tax | -$270,000 | $1,000 | $1,000 |
| Net income | -$161.00M | -$88.04M | -$48.61M |
| EBITDA | -$189.33M | -$114.63M | -$55.43M |
| EPS (basic) | -2.08 | -1.41 | -15.65 |
| EPS (diluted) | -2.08 | -1.41 | -15.65 |
| Weighted avg. shares (diluted) | 77.30M | 62.50M | 4.33M |
| Balance sheet | |||
| Cash & equivalents | $32.49M | $257.07M | $8.27M |
| Short-term investments | $709.66M | $484.93M | $179.41M |
| Receivables | $688,000 | $0 | — |
| Inventory | $1.56M | $0 | — |
| Current assets | $759.48M | $754.21M | $194.12M |
| PP&E, net | $15.60M | $272,000 | $69,000 |
| Goodwill | $10.30M | $0 | — |
| Intangibles | $575,000 | $0 | — |
| Total assets | $791.59M | $754.80M | $199.30M |
| Current liabilities | $30.84M | $21.37M | $14.25M |
| Long-term debt | $3.00M | $0 | — |
| Total debt | $3.00M | $0 | — |
| Total liabilities | $38.99M | $21.42M | $14.51M |
| Shareholders' equity | $752.60M | $733.38M | -$123.10M |
| Net debt | -$29.49M | -$257.07M | — |
| Shares outstanding | 80.69M | 76.15M | 5.22M |
| Cash flow statement | |||
| Operating cash flow | -$132.35M | -$78.71M | -$45.68M |
| Capital expenditure | $134,000 | $234,000 | — |
| Free cash flow | -$132.48M | -$78.95M | — |
| Investing cash flow | -$245.82M | -$300.76M | -$121.19M |
| Financing cash flow | $153.59M | $628.28M | $87.00M |
| Depreciation & amortization | $1.45M | $32,000 | $17,000 |
| Stock-based compensation | $26.68M | $11.40M | $1.53M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.